{
  "shared_fields": [
    "Publication Name",
    "Publication Year",
    "PDF number",
    "Trial name",
    "Cancer Type",
    "Sponsors",
    "Clinical Trial Phase",
    "NCT Number",
    "Mechanism of action",
    "Target Protein",
    "Type of therapy",
    "Dosage",
    "Type of dosing",
    "Number of doses per year",
    "Primary endpoint",
    "Secondary endpoint",
    "Median Age",
    "Biomarker Inclusion",
    "Biomarkers Inclusion Criteria",
    "Biomarkers Exclusion Criteria",
    "Major country where clinical trial is conducted",
    "Study start date",
    "Study completion date",
    "First results",
    "Trial run in Europe",
    "Trial run in US",
    "Trial run in China"
  ],
  "arm_specific_fields": [
    "Generic name",
    "Brand name",
    "Company EU",
    "Company US",
    "Company China",
    "Chemotherapy Naive",
    "Chemotherapy Failed",
    "Immune Checkpoint Inhibitor (ICI) Naive",
    "Immune Checkpoint Inhibitor (ICI) failed",
    "Ipilimumab-failure or Ipilimumab-refractory",
    "Anti PD-1/L1-failure or Anti PD-1/L1-refractory",
    "Mutation status",
    "BRAF-mutation",
    "NRAS-Mutation",
    "Biosimilar",
    "Line of Treatment",
    "Objective response rate (ORR)",
    "Complete Response (CR)",
    "Pathological Complete Response (pCR)",
    "Complete Metabolic Response (CMR)",
    "Disease Control Rate or DCR",
    "Clinical Benefit Rate (CBR)",
    "Duration of Response (DOR) rate",
    "Progression free survival (PFS) rate at 6 months",
    "Progression free survival (PFS) rate at 9 months",
    "Progression free survival (PFS) rate at 12 months",
    "Progression free survival (PFS) rate at 18 months",
    "Progression free survival (PFS) rate at 24 months",
    "Progression free survival (PFS) rate at 48 months",
    "Overall survival (OS) rate at 6 months",
    "Overall survival (OS) rate at 9 months",
    "Overall survival (OS) rate at 12 months",
    "Overall survival (OS) rate at 18 months",
    "Overall survival (OS) rate at 24 months",
    "Overall survival (OS) rate at 48 months",
    "Number of patients",
    "Median Progression free survival (PFS)",
    "Length of measuring PFS",
    "p-value of PFS",
    "Hazard ratio (HR) PFS",
    "Median Overall survival (OS)",
    "Length of measuring OS",
    "p-value of OS",
    "Hazard ratio (HR) OS",
    "Event-Free Survival (EFS)",
    "p-value of EFS",
    "Hazard ratio (HR) EFS",
    "Recurrence-Free Survival (RFS)",
    "p-value of RFS",
    "Length of measuring RFS",
    "Hazard ratio (HR) RFS",
    "Metastasis-Free Survival (MFS)",
    "Length of measuring MFS",
    "Hazard ratio (HR) MFS",
    "Time to response (TTR)",
    "Time to Progression (TTP)",
    "Time to Next Treatment (TTNT)",
    "Time to Treatment Failure (TTF)",
    "Median Duration of response or DOR",
    "Adverse events (AE)",
    "Treatment emergent adverse events (TEAE)",
    "Treatment-related adverse events (TRAE)",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 higher adverse events (AE)",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 higher treatment emergent adverse events (TEAE)",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 higher treatment-related adverse events (TRAE)",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 higher treatment-emergent adverse events (TEAE)",
    "Grade 4 treatment emergent adverse events",
    "Grade 5 treatment emergent adverse events",
    "Immune related adverse events (irAEs)",
    "Treatment-emergent adverse events (TEAE) led to treatment discontinuation",
    "Adverse events (AEs) leading to discontinuation",
    "Treatment-emergent adverse events (TEAE) led to death",
    "Adverse Events leading to death",
    "Serious Adverse Events (SAE)",
    "Serious treatment emergent adverse events",
    "Serious treatment related adverse events",
    "Cytokine Release Syndrome or CRS",
    "White blood cell (WBC) decreased",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Immune related adverse events (irAEs)",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Cytokine Release Syndrome or CRS",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Thrombocytopenia",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Neutropenia",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Leukopenia",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Nausea",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Anemia",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Diarrhea",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Colitis",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Hyperglycemia",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Neutrophil count decreased",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Constipation",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Dyspnea",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Cough",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Pyrexia",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Bleeding",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Pruritus",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Rash",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Pneumonia",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Thyroiditis",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Hypophysitis",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Hepatitis",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Pneumonitis",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 Alanine aminotransferase",
    "Grade ≥3 or Grade 3+ or Grade 3-5 or Grade 3-4 White blood cell (WBC) decreased"
  ]
} 